[Effects on simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia].
The therapeutic effects of simvastatin on hyperlipidemia and its protective effects on residual renal function (RRF) in continuous ambulatory peritoneal dialysis (CAPD) patients with hyperlipidemia were observed. Forty-seven CAPD patients were randomly divided into two groups, the treatment group and control group. The treatments of two groups were the same except that the treatment group patients were additionally given simvastatin 20 mg.d-1. The results were that, after 12-week treatment, the total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), and apoprotein B100 (ApoB100) in the treatment group significantly decreased, but high density lipoprotein (HDL) and apoprotein A1 (ApoA1) significantly increased compared with the control group (all P < 0.05); one year later, RRF of patients of both groups all decreased but there was no significant difference between them. The results suggest that simvastatin can effectively normalize lipidemia, but has no protective effect on RRF in CAPD patients.